Tobira Therapeutics, Inc. (NASDAQ:TBRA) has finally revealed on Monday the results of the Phase 2b safety and efficacy clinical trial for cenicriviroc (CVC) treating non-alcoholic steatohepatitis (NASH) among 289 patients suffering from liver fibrosis, a study that is also known as CENTAUR. Study Results The study failed to meet its main endpoint but it did […]
